Zhejiang Langhua Pharmaceutical, a wholly owned subsidiary of Viva Biotech, (HKG:1873), passed the current good manufacturing practices (cGMP) onsite inspection conducted by the US Food and Drug Administration (FDA), according to a Thursday bourse filing.

The pharmaceutical company recently received the establishment inspection report from the US FDA, confirming the inspection's completion in line with the Code of Federal Regulations Title 21 (21 CFR).

The inspection, done in the second half of 2024, covered quality systems, materials, production, packaging and labeling systems, equipment and facilities, and laboratory control.